NXTC
NextCure Inc
NASDAQ: NXTC · HEALTHCARE · BIOTECHNOLOGY
$9.21
+3.02% today
Updated 2026-04-30
Market cap
$34.70M
P/E ratio
—
P/S ratio
9.52x
EPS (TTM)
$-19.65
Dividend yield
—
52W range
$4 – $16
Volume
0.1M
NextCure Inc (NXTC) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $6.35M | $22.38M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | +252.6% | -100.0% | — | — | — | — |
| Cost of revenue | $582000.00 | $1.68M | $34.22M | $46554.00 | $4.30M | $4.48M | $3.68M | $2.87M | $2.19M |
| Gross profit | $-582000.00 | $-1.68M | $-27.87M | $22.38M | $-4.30M | $-4.48M | $-3.68M | $-2.87M | $-2.19M |
| Gross margin | — | — | -439.1% | 100.0% | — | — | — | — | — |
| R&D | $12.95M | $19.79M | $34.22M | $46.55M | $50.19M | $54.20M | $47.93M | $41.49M | $44.92M |
| SG&A | $2.60M | $3.41M | $9.61M | $17.05M | $20.57M | $21.71M | $19.71M | $15.72M | $12.69M |
| Operating income | $-15.55M | $-23.20M | $-37.48M | $-41.23M | $-70.77M | $-75.91M | $-67.64M | $-59.75M | $-57.62M |
| Operating margin | — | — | -590.5% | -184.2% | — | — | — | — | — |
| EBITDA | $-14.97M | $-21.10M | $-34.79M | $-37.81M | $-66.59M | $-71.78M | $-63.95M | $-54.34M | $-55.43M |
| EBITDA margin | — | — | -548.2% | -169.0% | — | — | — | — | — |
| EBIT | $-15.55M | $-22.77M | $-37.48M | $-41.23M | $-70.77M | $-75.91M | $-67.64M | $-57.21M | $-57.62M |
| Interest expense | $0.00 | $0.00 | $209000.00 | $183000.00 | $77000.00 | $5.30M | — | — | — |
| Income tax | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-15.47M | $-22.80M | $-33.74M | $-33.19M | $-69.39M | $-69.43M | $-62.72M | $-55.65M | $-55.84M |
| Net income growth (YoY) | — | -47.4% | -48.0% | +1.6% | -109.1% | -0.1% | +9.7% | +11.3% | -0.3% |
| Profit margin | — | — | -531.5% | -148.3% | — | — | — | — | — |